Predictive value of common clinical and laboratory parameters in predicting response to Anti thyroid drug therapy in Graves’ Hyperthyroidism – A prospective study
About this article
Abstract
Purpose: Graves’ hyperthyroidism (GH) is commonly treated by antithyroid drugs (ATD). This study was undertaken to identify those clinical factors that could predict sustained remission with ATD so as to avoid unwanted therapy.
Approach: Subjects (n=134) diagnosed with GH were consecutively recruited. Carbimazole was administered for 18 months as per titration regimen and subsequently followed up for upto 1 month to detect relapse of thyrotoxicosis.
Results: In final analysis of 115 subjects, 61 remained in remission while thyrotoxicosis recurred in 54 subjects during followup. Parameters associated with remission for at least 6 months were : smaller goiter, lower free triiodothyronine (FT3 ) values at onset and euthyroidism in response to ATD within 3 – 6 months.
Conclusions: 50% of patients went into remission with carbimazole therapy for 18 months. Subjects who fail to achieve euthyroidism with 6 months of ATD should be offered radioiodine or surgery.
References
A.P. Weetman, Graves’ disease, N Engl J Med 343 (2000) 1236-1248.
L. Wartofsky, D. Glinoer, S.Solomon, R. Nagataki, R. Lagasse , Differences and similarities in the diagnosis and treatment of Graves’ disease in Europe, Japan and the United States, Thyroid (1991)129-135.
D. Glinoer, D. Hesch, R. Lagasse, P. Laurberg, The management of hyperthyroidism due to Graves’disease in Europe in 1986. Results of an international survey, Acta Endocrinol S 285(1987) 4-23.
L.Wartofsky, Low remission after therapy for Graves’ disease: possible relation of dietary iodine with antithyroid therapy results, J Am Med Assoc 226(1973)1083-1088.
A.J .Hedley, R.E. Young, S.J. Jones, W.D. Alexander, P.D. Bewsher, Scottish automated follow -up register group, Antithyroid drugs in the treatment of hyperthyroidism of Graves’ disease: long term follow-up of 434 patients, Clin Endocrinol (Oxf) 31(1989) 209-218.
View more references (16)
H. Schleusner, J. Schwander, C.Fischer et al, Prospective multicenter study on the prediction of relapse after antithyroid dr ug treatment in patients with Graves’ disease, Acta Endocrinol (Copenh) 120(1989) 689-701.
P. Vitti, T. Rago, L. Chiovato, Clinical features of patients with Graves’ disease undergoing remission after antithyroid drug treatment, Thyroid 7(1997) 369-375.
World Health Organisation. Indicators for assessing iodine deficiency disorders and their control programs through salt iodination. WHO/UNICEF/ICCIDD Report 1994.
S.C. Werner, Modification of the classification of the eye changes in Graves’ disease: recommendations of the ad hoc committee of the American Thyroid Association, J Clin Endocrinol Metab 44 (1977)203-209.
D.A. Meier, M.M. Kaplan. Radioiodine uptake and thyroid scintiscanning. Endocrinol Metab Clin N Am 30(2001) 291–313.
H. Allannic, R. Fauchet, J. Orgiazzi et al, Antithyroid drugs and Graves’ disease: a prospective randomized evaluation of the efficacy of treatment duration, J Clin Endocrinol Metab 70(1990) 675-679.
R.V. Garcia Mayor , C. Paramo , R. LunaCano, L.F. Perez Mendez, J.C. Galofre, A. Andrade, Antithyroid drug and Graves’ hyperthyroidism .Signif icance of treatment duration and TRAb determination on lasting remiss ion, J Endocrinol Inv 15(1992)815-820.
D. Maugendre, A. Gatel, L. Campion et al, Antithyroid drugs and Graves’ disease – a prospective randomized assessment of long term treatment. Clin Endocrinol 50(1999)127-132.
P. Abraham, A. Avenell, W.A. Watson, C.M. Park, J.S. Bevan. A systematic review of drug therapy for Graves’ hyperthyroidism. Cochrane Database of Systematic Reviews 2 (2005) CD 003420 (DOI: 10.1002/14651858).
P. Abraham, A. Avenell, C.M. Park, W.A. Watson, J.S. Bevan. A systematic review of drug therapy for Graves’ hyperthyroidism. Eur J Endocrinol 153(2005) 489-498.
J.N. Talbot, F. Duron, R. Feron, P. Aubert, G. Milhaud, Thyroglobulin, thyr otropin and thyrotropin binding inhibiting immunoglobulins assayed at the withdrawal of antithyr oid drug therapay as predictors of relapse of Graves’ disease within one year. J Endocrinol Inv 12 (1989)589-595.
A. Allahabadia, J. Daykin, R.L. Holder, Mc. Sheppard, S.C.L. Gough, J.A. Franklyn. Age and gender predict the outcome of treatment for Graves’ hyperthyroidism. J Clin Endocrinol Metab 85 (2000)1038-1042.
F. Bolaños, M. Gonza lez-Ortiz, H. Duron, C. Sanchez. Remission of Graves' hyperthyroidism treated with methimazole.Rev Inv Clin 54(2002) 307-310.
I.M. Bringmann, B.L. van Leeuwen, G. Hennemann, G.J. Beckett, A.D. Toft, Outcome of treatment of hyperthyroidism, J Endocrinol Inv 22(1999) 250-256.
C. Marcocci, D. Gianchecchi, I. Masini et al, A reappraisal of the role of methimazole and other factors on the efficacy and outcome of radioiodine therapy of Graves’ hyperthyroidism. J Endocrinol Inv 13(1990)513-520.
R. Sankar, T. Sekhri, G. Sripathy, R.P. Walia, S.K. Jain, Radioiodine therapy in Graves’ hyperthyroidism: a prospective study from a tertiary referral centre in North India. J Assoc Physic Ind 53(2005) 603-606.